Literature DB >> 20823136

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.

Philip A Beer1, Christina A Ortmann, Frank Stegelmann, Paola Guglielmelli, John T Reilly, Thomas S Larsen, Hans C Hasselbalch, Alessandro M Vannucchi, Peter Möller, Konstanze Döhner, Anthony R Green.   

Abstract

Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in de novo acute myeloid leukemia, was not detected in 172 patients with a myeloproliferative neoplasm. In patients with a prior MPL W515L-mutant myeloproliferative neoplasm, leukemic transformation was accompanied by MPL-mutant leukemic blasts, was seen in the absence of prior cytoreductive therapy and often involved loss of wild-type MPL by mitotic recombination. Moreover, clonal analysis of progenitor colonies at the time of leukemic transformation revealed the presence of multiple genetically distinct but phylogenetically-related clones bearing different TP53 mutations, implying a mutator-phenotype and indicating that leukemic transformation may be preceded by the parallel expansion of diverse hematopoietic clones.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823136      PMCID: PMC2995575          DOI: 10.3324/haematol.2010.029306

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo-Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

2.  Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

Authors:  Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

3.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Authors:  Audrey Petitjean; Ewy Mathe; Shunsuke Kato; Chikashi Ishioka; Sean V Tavtigian; Pierre Hainaut; Magali Olivier
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

4.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

5.  BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.

Authors:  Tomasz Stoklosa; Tomasz Poplawski; Mateusz Koptyra; Margaret Nieborowska-Skorska; Grzegorz Basak; Artur Slupianek; Marina Rayevskaya; Ilona Seferynska; Larry Herrera; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Authors:  Alexandre Theocharides; Marjorie Boissinot; François Girodon; Richard Garand; Soon-Siong Teo; Eric Lippert; Pascaline Talmant; Andre Tichelli; Sylvie Hermouet; Radek C Skoda
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

7.  Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Authors:  Norihiko Kawamata; Seishi Ogawa; Go Yamamoto; Soren Lehmann; Ross L Levine; Yana Pikman; Yasuhito Nannya; Masashi Sanada; Carl W Miller; D Gary Gilliland; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084

8.  Activating mutations in human acute megakaryoblastic leukemia.

Authors:  Sébastien Malinge; Christine Ragu; Veronique Della-Valle; Didier Pisani; Stefan N Constantinescu; Christelle Perez; Jean-Luc Villeval; Dirk Reinhardt; Judith Landman-Parker; Lucienne Michaux; Nicole Dastugue; André Baruchel; William Vainchenker; Jean-Pierre Bourquin; Virginie Penard-Lacronique; Olivier A Bernard
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

9.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

Authors:  Peter J Campbell; E Joanna Baxter; Philip A Beer; Linda M Scott; Anthony J Bench; Brian J P Huntly; Wendy N Erber; Rajko Kusec; Thomas Stauffer Larsen; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; Martin Griesshammer; John T Reilly; Betty Y Cheung; Claire N Harrison; Anthony R Green
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

10.  MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

Authors:  Philip A Beer; Peter J Campbell; Linda M Scott; Anthony J Bench; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Hans C Hasselbalch; Richard Bowman; Keith Wheatley; Georgina Buck; Claire N Harrison; Anthony R Green
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

View more
  6 in total

1.  Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Authors:  John Mascarenhas; Mark L Heaney; Vesna Najfeld; Elizabeth Hexner; Omar Abdel-Wahab; Raajit Rampal; Farhad Ravandi; Bruce Petersen; Gail Roboz; Eric Feldman; Nikolai Podoltsev; Dan Douer; Ross Levine; Martin Tallman; Ronald Hoffman
Journal:  Leuk Res       Date:  2012-08-28       Impact factor: 3.156

2.  Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

Authors:  Daniela Pietra; Angela Brisci; Elisa Rumi; Sabrina Boggi; Chiara Elena; Alessandro Pietrelli; Roberta Bordoni; Maurizio Ferrari; Francesco Passamonti; Gianluca De Bellis; Laura Cremonesi; Mario Cazzola
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

3.  Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Authors:  B Kubesova; S Pavlova; J Malcikova; J Kabathova; L Radova; N Tom; B Tichy; K Plevova; B Kantorova; K Fiedorova; M Slavikova; V Bystry; J Kissova; B Gisslinger; H Gisslinger; M Penka; J Mayer; R Kralovics; S Pospisilova; M Doubek
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

4.  Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing.

Authors:  Jee-Soo Lee; Heewon Seo; Kyongok Im; Si Nae Park; Sung-Min Kim; Eun Kyoung Lee; Jung-Ah Kim; Joon-Hee Lee; Sunghoon Kwon; Miyoung Kim; Insong Koh; Seungwoo Hwang; Heung-Woo Park; Hye-Ryun Kang; Kyoung Soo Park; Ju Han Kim; Dong Soon Lee
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

5.  Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.

Authors:  Simona Salati; Elena Genovese; Chiara Carretta; Roberta Zini; Niccolò Bartalucci; Zelia Prudente; Valentina Pennucci; Samantha Ruberti; Chiara Rossi; Sebastiano Rontauroli; Elena Enzo; Laura Calabresi; Manjola Balliu; Carmela Mannarelli; Elisa Bianchi; Paola Guglielmelli; Enrico Tagliafico; Alessandro M Vannucchi; Rossella Manfredini
Journal:  Sci Rep       Date:  2019-07-22       Impact factor: 4.379

Review 6.  Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease.

Authors:  Francesco Mannelli
Journal:  J Clin Med       Date:  2021-01-23       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.